Shining a Light on Non-Hodgkin Lymphoma

Program Overview

Community hematologist/oncologists (hem-oncs) are tasked with staying up to date on the latest clinical trial data across multiple oncologic disease states, which typically entails proficiency with rapidly changing management guidelines. During two of the largest global hem-onc conferences, American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Hybrid Congress, data were presented that highlight new findings and treatment updates in patients with non-Hodgkin lymphoma (NHL).  Our expert hem-onc faculty, Drs. Sairah Ahmed and Ann LaCasce, distill the pivotal clinical trial data across diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and other subtypes of NHL (eg, marginal zone lymphoma) and answer practice-based questions from their community hem-onc colleagues.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the newer US Food and Drug Administration–approved therapies in various non-Hodgkin lymphoma subtypes
• Summarize the most recent clinical trial data on investigational therapies in non-Hodgkin lymphoma, emerging from recent hematology/oncology conferences
• Discuss approaches to implementation of new findings and therapeutic options in non-Hodgkin lymphoma therapies